Stinkens, R. http://orcid.org/0000-0001-9382-2457
van der Kolk, B. W.
Jordan, J.
Jax, T.
Engeli, S.
Heise, T.
Jocken, J. W.
May, M. http://orcid.org/0000-0002-7513-4244
Schindler, C.
Havekes, B.
Schaper, N.
Albrecht, D.
Kaiser, S.
Hartmann, N.
Letzkus, M.
Langenickel, T. H.
Goossens, G. H.
Blaak, E. E.
Article History
Received: 17 August 2017
Accepted: 19 February 2018
First Online: 2 March 2018
Competing Interests
: This study was funded by Novartis Pharma AG, Basel, Switzerland. J.J. served as consultant for Novartis, Boehringer-Ingelheim, Sanofi, Orexigen, Riemser, Vivus and is cofounder of Eternygen GmbH. D.A., S.K., N.H., L.M. and T.H.L are employees of Novartis. R.S., B.v.d.K., T.J, S.E., M.M., C.S., J.W.E.J., B.H., N.S., G.H.G. and E.E.B. have nothing to disclose. TH is part-owner of Profil, a private research institute, that has received research grants from Adocia, Biocon, Dance Pharmaceuticals, Eli Lilly, Johnson&Johnson, Julphar, Medimmune, Mylan, Nordic Bioscience, Novo Nordisk, Poxel, Roche Diagnostics, Saniona, Sanofi, Senseonics, SkyePharma and Zealand Pharma. In addition, TH is member of advisory boards of Novo Nordisk and received speaker honoraria and travel support from Eli Lilly, Novo Nordisk and Sanofi.